(PDF) P3.01-79 Intracerebral Efficacy of Immune Check-Point

P3.01-79 Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1639

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

Immune Checkpoint Inhibition in Patients With Brain Metastases

Annals of Translational Medicine

English

Impact of Lymphopenia on Survival Following Stereotactic Radiosurgery and Immune-Checkpoint Inhibitors Among Patients With Brain Metastases

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-53 Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients With T790m-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy and Safety of Icotinib in Patients With Brain Metastases From Lung Adenocarcinoma

OncoTargets and Therapy

English